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Hereditary hemochromatosis (HH) is a disorder of iron metabolism
in which enhanced iron absorption of dietary iron causes increased
iron accumulation in the liver, heart, and pancreas. Most individ-
uals with HH are homozygous for a C282Y mutation in the HFE
gene. The function of HFE protein is unknown, but it is hypothe-
sized that it acts in association with 2-microglobulin and trans-
ferrin receptor 1 to regulate iron uptake from plasma transferrin by
the duodenum, the proposed mechanism by which body iron levels
are sensed. The aim of this study was to test this hypothesis by
comparing clearance of transferrin-bound iron in Hfe knockout
(KO) mice with that observed in C57BL6 control mice. The mice
were fed either an iron-deficient, control, or iron-loaded diet for 6
weeks to alter body iron status. The mice then were injected i.v.
with 59Fe-transferrin, and blood samples were taken over 2 h to
determine the plasma 59Fe turnover. After 2 h, the mice were killed
and the amount of radioactivity in the duodenum, liver, and kidney
was measured. In both Hfe KO and C57BL6 mice, plasma iron
turnover and iron uptake from plasma transferrin by the duode-
num, liver, and kidney correlated positively with plasma iron
concentration. However, duodenal iron uptake from plasma trans-
ferrin was decreased in the Hfe KO mice compared with the control
mice. Despite this difference in duodenal uptake, the Hfe KO mice
showed no decrease in iron uptake by the liver and kidney or
alteration in the plasma iron turnover when compared with
C57BL6 mice. These data support the hypothesis that HFE regu-
lates duodenal uptake of transferrin-bound iron from plasma, and
that this mechanism of sensing body iron status, as reflected in
plasma iron levels, is impaired in HH.
Hereditary hemochromatosis (HH) is a common autosomalrecessive inherited disorder of iron metabolism. Most in-
dividuals with HH are homozygous for a missense (C282Y)
mutation in the HFE gene that encodes a major histocompati-
bility class 1-like protein (1–4). One in 200 adults of Caucasian
descent have this genotype (1, 2). The disease is characterized by
increased absorption of dietary iron by the gastrointestinal tract
and the progressive deposition of iron in the parenchymal cells,
which can result in hepatic fibrosis, cirrhosis, and hepatocellular
carcinoma (3).
The expression of HFE protein is widespread in many tissues,
including the gastrointestinal tract. In the duodenum, HFE is
localized in the perinuclear region of the enterocytes in the crypt
region but not in the villus region where iron is absorbed from
the lumen (5). The localization of HFE in the crypt enterocytes
suggests that its function is to regulate, rather than directly
participate in, iron absorption.
Dietary iron absorption is a complex process and is inversely
regulated by the body iron status. Thus, iron absorption is
increased with iron deficiency and decreased with iron overload.
The enterocytes in the crypt region of the duodenum, which take
up iron from plasma transferrin at their basolateral surfaces,
migrate to the villus region where they differentiate into ab-
sorptive cells that absorb dietary iron from their luminal surfaces
(6). The iron level in these differentiating cells, which is thought
to be predetermined in the crypt cells, controls the expression of
iron transporters such as divalent metal transporter 1 and
ferroportin 1 and, subsequently, the rate of iron absorption from
the lumen. In HH, dietary iron absorption is increased even in
the presence of elevated plasma transferrin saturation and
increased hepatic iron stores (7). This observation suggests that
the regulation of iron absorption by the body iron stores is
impaired, and that the duodenum is acting as if it were relatively
iron-deficient, with increased expression of iron transporters
leading to increased iron absorption (8, 9).
The precise function of HFE in the crypt cells is unknown. The
cells express transferrin receptor 1 (TfR1) [and possibly trans-
ferrin receptor 2 (TfR2)] which mediates the uptake of trans-
ferrin-bound iron (10–12). HFE protein has been found to be
associated closely with TfR1 in the crypt cells where it could
influence the rate of uptake of transferrin-bound iron uptake by
the crypt cells (13).
In this study, we tested the hypothesis that HFE normally
participates in sensing body iron stores by regulating uptake of
transferrin-bound iron from the plasma by the duodenum, and
that this function is impaired in HH. Hfe knockout (KO) mice
and C57BL6 control mice were fed iron-deficient, basal, and
iron-loaded diets to alter their body iron status. The mice were
injected i.v. with 59Fe-transferrin, and the uptake of plasma iron
by the duodenum was measured. Results indicated that iron
uptake from the plasma by the duodenum of the Hfe KO mice
was decreased significantly compared with that of the C57BL6
control mice, supporting the hypothesis that HFE participates in
the mechanism by which body iron levels are sensed in the
duodenal crypt cells.
Materials and Methods
Animals. A mouse model of HH was used in which the Hfe gene
has been disrupted by homologous recombination, as described
by Zhou et al. (14). Female Hfe KO and C57BL6 mice (obtained
from Animal Resource Centre, Murdoch, Western Australia)
were fed a purified diet (AIN-93) as recommended by the
American Institute of Nutrition (15) ad libitum from weaning at
3 weeks of age for 6 weeks. Hfe KO and C57BL6 mice were
divided into three groups and were fed either an iron-deficient
diet (10 mgkg), a basal iron diet containing 35 mgkg added
iron as ferric citrate, or an iron-loaded diet supplemented with
20 gkg carbonyl iron (Sigma). This study was approved by The
University of Western Australia Animal Ethics Committee.
Plasma Iron Clearance. Mouse transferrin and albumin were pre-
pared and labeled with iron-59, iodine-125, and iodine-131,
respectively (NEN, Melbourne, Australia), as described (16). Hfe
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KO and C57BL6 control mice were injected in the lateral tail
vein with 30 l of mixture containing 150 g of 59Fe-125I-
transferrin and 150 g of 131I-albumin. Blood samples (50 l)
were collected in hematocrit tubes from the tail vein at 2, 30, 60,
and 90 min. Two h after the injection, the mice were anesthetized
with an i.p. injection of sodium pentobarbital. Blood was col-
lected from the right ventricle of the heart, and the mice were
perfused through the left ventricle with 10 ml of heparinized
saline. The duodenum, liver, and kidneys were removed and
homogenized by using a Dounce glass homogenizer (Kontes).
Trichloroacetic acid (final concentration 10%) was added to an
aliquot of the homogenized tissues to precipitate the protein-
bound 125I and 131I. After 10 min on ice, the protein precipitate
and supernatant were separated by centrifugation. Radioactivity
was measured in the tissues and plasma with an LKB-Wallac
1281 Compugamma gamma counter. The amount of 59Fe in the
plasma samples taken at various time intervals after the injection
of radioactivity was used to calculate the rate of plasma iron
clearance. The specific activity of 59Fe-transferrin was corrected
for the different pool sizes of circulating transferrin-bound iron
in mice fed diets containing differing levels of iron using the
plasma iron concentration. The amount of 131I-albumin in the
plasma and tissues was used to determine the plasma volume and
the amount of plasma remaining in the tissue after perfusion.
Tissue 59Fe uptake was corrected for transferrin-bound iron by
measuring the amount of 125I-transferrin in the tissues (17).
Analytical Methods. Liver non-heme iron concentration was mea-
sured by the method of Kaldor (18), and plasma iron concen-
tration was determined by an approved method of the Interna-
tional Committee for Standardization in Haematology (19).
Statistical Analysis. Results were expressed as means  SE where
appropriate. Differences between groups were determined by
performing ANOVA and a Tukey’s multiple comparison test by
using the GraphPad PRISM program (GraphPad, San Diego).
Regression analysis was performed where appropriate to deter-
mine whether there was a linear relationship between variables;
analysis of co-variance was performed to determine differences
in the slope and intercept between two regression analyses.
Regression analysis and analysis of co-variance were performed
with the Statistics Package for Social Scientists (SPSS, V.10).
Statistical significance was accepted for P  0.05.
Results
Liver Non-Heme Iron Concentration. Hfe KO and C57BL6 mice
were fed either an iron-deficient, basal, or iron-loaded diet. In
both the Hfe KO and C57BL6 mice, there was a significant
increase in the liver non-heme iron levels in mice fed an
iron-loaded diet compared with the basal and iron-deficient diets
after 6 weeks (Fig. 1). However, there was significantly more
non-heme iron in the liver of the Hfe KO mice compared with
the C57BL6 control mice for all iron diets (Fig. 1).
Plasma Iron Concentration. Plasma iron concentrations increased
with dietary iron loading in both C57BL6 and Hfe KO mice
(Fig. 2). Hfe KO mice have significantly higher plasma iron
concentrations than C57BL6 mice fed control and iron-loaded
diets, but not those fed the iron-deficient diet.
Transferrin-Bound Iron Uptake by the Duodenum. To determine the
uptake of plasma transferrin-bound iron by the duodenum, the
Hfe KO and C57BL6 mice were given an i.v. injection of
59Fe-transferrin, and the amount of 59Fe in the duodenum was
measured after 2 h. There was an increase in the uptake of
plasma transferrin-bound iron by the duodenum with increasing
plasma iron concentrations in both Hfe KO and control mice.
The uptake of plasma transferrin-bound iron by the duodenum
in both the Hfe KO and C57BL6 control mice was correlated
linearly with the plasma iron levels (Hfe KO, r2 0.57, P 0.004;
C57BL6, r2  0.44, P  0.009; Fig. 3A) However, there was a
significant difference in the amount of uptake of plasma trans-
ferrin-bound iron by the duodenum in the Hfe KO and C57BL6
control mice.
This difference in uptake depended on the plasma iron
concentration. In fact, at low plasma iron concentrations, plasma
transferrin-bound iron uptake was similar in the Hfe KO and
control mice. However, as the plasma iron concentration in-
creased, plasma transferrin-bound iron uptake in the Hfe KO
mice increased less than in the control mice. Analysis of co-
variance was performed on the two regression lines for duodenal
uptake vs. plasma iron concentration for Hfe KO and control
Fig. 1. Liver non-heme iron concentration in Hfe KO (white bars) and
C57BL6 (cross-hatched bars) control mice fed an iron-deficient, normal (con-
trol) or iron-loaded diet for 6 weeks. Results are expressed as the means SE
where n 4–9 mice per group. Significant differences between groups: *, P
0.001, Hfe KO vs. C57BL6 mice; †, P 0.001, iron-loaded diet vs. normal and
iron-deficient diet.
Fig. 2. Plasma iron concentration in Hfe KO (white bars) and C57BL6
(cross-hatched bars) mice fed an iron-deficient, normal, or iron-loaded diet for
6 weeks. The results are given as means  SE where n  4–9 mice per group.
Significant differences: *, P 0.05 Hfe KO vs. C57BL6 mice; †, P 0.001, Hfe
KO mice iron-loaded diet vs. normal and iron-deficient diet; §, P  0.05
C57BL6 mice iron-loaded diet vs. normal and iron-deficient diet.











mice (Fig. 3A); it demonstrated a significant difference in the
slope of the two regression lines (P  0.012) but no significant
difference in the value of the intercepts (P  0.37).
Increased uptake of plasma transferrin-bound iron by the
duodenum correlated with increasing liver non-heme iron levels
in both Hfe KO and control mice. Regression analysis indicated
that there was a correlation between duodenal uptake of plasma
transferrin-bound iron and the liver non-heme concentration in
the Hfe KO and control mice (Hfe KO, r2  0.51, P  0.009;
C57BL6, r2 0.75, P 0.001; Fig. 3B). Furthermore, there was
significantly lower uptake of transferrin-bound iron from plasma
by the duodenum of the Hfe KO mice compared with the control
mice. As the liver non-heme iron concentration increased,
duodenal uptake of plasma transferrin-bound iron in the Hfe KO
mice increased more slowly than in the control mice. Analysis of
co-variance was undertaken on the two regression lines for
duodenal uptake vs. liver non-heme iron concentration in Hfe
KO and C57BL6 mice. There was a significant difference
between both the slope (P 0.002) and intercept (P 0.003) of
the two regression lines.
Uptake of Transferrin-Bound Iron by the Liver and Kidney. The
uptake of 59Fe-transferrin by the liver and kidney in the Hfe KO
and control mice also depended on the plasma iron concentra-
tion. There was a positive correlation between the plasma iron
concentration and hepatic iron uptake in the Hfe KO and
C57BL6 mice (Hfe KO, r2  0.91, P  0.001; C57BL6, r2 
0.30, P  0.02; Fig. 4A), and this was also true for uptake by
kidney (Hfe KO, r2  0.61, P  0.002; C57BL6, r2  0.40, P 
0.012; Fig. 4B). The uptake of iron by the liver was approximately
two-fold greater than by the kidney at any given plasma iron
concentration in both types of mice. However, analysis of
co-variance showed there was no significant difference in the
Fig. 3. Plasma transferrin-bound iron uptake by the duodenum in Hfe KO ()
and C57BL6 () mice. Results are plotted in relation to plasma iron concen-
tration (A) or liver non-heme iron concentration (B). There was a positive
correlation of duodenal uptake of plasma transferrin-bound iron by the Hfe
KO and C57BL6 control mice with the plasma iron levels (Hfe KO, r2  0.57,
P  0.004; C57BL6, r2  0.44, P  0.009) and liver non-heme iron levels (Hfe
KO, r2 0.51, P 0.009; C57BL6, r2 0.75, P 0.001). There was a significant
difference in the slope (P  0.012) but not in the value of the intercepts (P 
0.37) of the regression lines for plasma transferrin-bound iron uptake with
increasing plasma iron levels for Hfe KO vs. the C57BL6 control mice. There
was a significant difference between both the slope (P 0.002) and intercept
(P  0.003) of the regression lines for plasma transferrin-bound iron uptake
with increasing liver non-heme iron levels for Hfe KO vs. the control mice.
Fig. 4. Transferrin-bound iron uptake by the liver (A) and kidney (B) in Hfe
KO () and C57BL6 () mice. There was a positive correlation between the
plasma iron concentration and the plasma transferrin-bound iron uptake by
the liver (Hfe KO, r2 0.91, P 0.001; C57BL6, r2 0.30, P 0.02) and kidney
(Hfe KO, r2  0.61, P  0.002; C57BL6, r2  0.40, P  0.012) in Hfe KO and
control mice. There was no significant difference in the regression lines for the
uptake of plasma transferrin-bound iron by the liver or the kidney with
increasing plasma iron concentrations in the Hfe KO vs. the C57BL6 mice.
(Liver: slope, P  0.11, intercept, P  0.28; kidney: slope, P  0.61, intercept,
P  0.61).
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amount of iron taken up by the liver or the kidney with increasing
plasma iron concentrations in the Hfe KO vs. the C57BL6 mice.
(Liver: slope, P  0.11; intercept, P  0.28. Kidney: slope, P 
0.61; intercept, P  0.61; Figs. 4A and 4B).
Plasma Iron Turnover. The plasma iron turnover in the Hfe KO and
C57BL6 mice was calculated from the rate of clearance of 59Fe
from the plasma over 2 h. The plasma iron turnover increased in
a linear manner with increasing plasma iron concentrations in
both the Hfe KO and C57BL6 mice (Hfe KO, r2  0.79, P 
0.001; C57BL6, r2  0.60, P  0.001). There was no significant
difference in the plasma iron turnover with increasing plasma
iron concentrations in the Hfe KO vs. the control mice (analysis
of co-variance: slope, P  0.20; intercept, P  0.40; Fig. 5).
Discussion
In this study, we demonstrated that there was a significant
impairment in the uptake of transferrin-bound iron by the
duodenum in the Hfe KO mice as compared with the control
mice, which became more obvious as iron stores increased. This
finding indicates that in the absence of Hfe, iron uptake by the
duodenum still reflects iron status, but this process is less
sensitive to the body iron stores. This inhibitory effect was
specific to the duodenum, as no significant differences were
observed in the uptake of transferrin-bound iron by the liver or
kidney in the Hfe KO mice compared with control mice,
regardless of the plasma iron concentration. Also, there was no
overall change in the plasma iron turnover in the Hfe KO
compared with the control mice. The plasma iron turnover
reflects mainly the rate of clearance of iron by the bone marrow
for erythropoiesis. This result indicates that iron uptake by the
erythroid cells was not regulated by HFE or altered in the Hfe
KO model of HH.
Impaired uptake of transferrin-bound iron by the duodenum
of the Hfe KO mice would lead to a relatively iron-deficient
duodenum. This observation is consistent with findings from
studies in HH patients that have shown that the enterocytes have
increased iron-regulatory protein activity and reduced ferritin
levels (20, 21). Furthermore, expression of both iron transport-
ers, divalent metal transporter 1 and ferroportin 1, is up-
regulated in HH patients (22, 23). In the Hfe KO mice, divalent
metal transporter 1 mRNA and protein were reported to be
increased (24, 25). However, these observations were not repro-
duced by a study using another Hfe KO mouse model or the
2-microglobulin (2M) KO mouse model of iron overload (26).
Although we did not measure dietary iron absorption in this
study, two other studies (25, 27) have shown that the absorption
of luminal iron by the duodenum was increased in the Hfe KO
mice compared with the control mice. This finding could be
explained by the results of the present study showing impaired
uptake of transferrin-bound iron from plasma by the cells in the
crypt region of the duodenum in Hfe KO mice compared with
that seen in the control mice. The reduced uptake of iron would
lead to relatively decreased iron levels in duodenal crypt cells
that do not reflect the high plasma iron levels in the Hfe KO
mice. In turn, as the crypt cells migrate to the villus region of the
duodenum and undergo differentiation into absorptive cells, the
absorption of dietary iron from the intestinal lumen would be
inappropriately up-regulated in the Hfe KO mice.
Macrophages have some similarities to the enterocytes from
the crypt region of the duodenum in that both types of cells
express high levels of HFE and are relatively iron-deficient in
HH. A recent study of macrophages by Montosi et al. (28)
obtained results qualitatively similar to ours and showed that
transferrin-bound iron uptake by macrophages from HH pa-
tients was decreased.
The mechanism involved in the HFE regulation of transferrin-
bound iron uptake by the crypt cells of the duodenum and the
macrophages is unknown. Wild-type HFE is associated closely
with 2M, and TfR1 and is expressed on the cell surface and in
the TfR1-containing endosomes (29–33). A number of experi-
ments have been undertaken in which wild-type HFE was
overexpressed in cultured cells and the overexpressed wild-type
HFE decreased transferrin-bound iron uptake (32–37). How-
ever, Waheed et al. (37) recently reported that when both
wild-type HFE and 2M were overexpressed in Chinese hamster
ovary (CHO) cells, the cellular uptake of transferrin-bound iron
was increased, which was attributed to an increased recycling
rate of TfR1 through the cell. This stimulation of uptake of
transferrin-bound iron by HFE was seen only if 2M also was
overexpressed in the CHO cells. If the function of HFE ex-
pressed in CHO cells provides a model for HFE’s function in the
duodenal crypt cells, as Waheed et al. (37) proposed, then a
stable wild-type HFE-2M complex would be necessary to
enhance TfR1-mediated cellular uptake of transferrin-bound
iron by duodenal crypt cells. C282Y HFE does not associate with
either 2M or TfR1, and its cell surface expression is greatly
reduced (29, 30). Thus, it is unlikely that C282Y HFE could
enhance cellular uptake of transferrin-bound iron by duodenal
crypt cells. The relative decrease of transferrin-bound iron
uptake compared with wild-type HFE in CHO cells is consistent
with our observations of decreased transferrin-bound iron up-
take by the duodenum in the Hfe KO mice and by macrophages
from HH patients (28).
For many years, it has been proposed that there is another
factor—termed a ‘‘stores regulator’’—in the plasma that controls
whole-body iron homeostasis and responds to changes in body
iron stores (38). A number of candidates for this stores regulator
have been suggested, such as transferrin-bound iron, serum
ferritin, serum TfR1, and the recently identified hepcidin (39–
42). Hepcidin is a hepatic peptide which is secreted into the
blood; in its absence, iron overload with characteristics similar to
HH develops (42). Hepcidin has been proposed by Nicolas et al.
(42) to be the stores regulator in plasma that reflects hepatic iron
levels and interacts with the HFE-2M-TfR1 complex in the
duodenum to regulate iron uptake. In the presence of C282Y
HFE, as in HH or animal models of HH such as the Hfe and 2M
KO mice, this interaction may be impaired, contributing to the
Fig. 5. Plasma iron turnover in Hfe KO () and C57BL6 control () mice fed
an iron-deficient, normal, or iron-loaded diet. Plasma iron turnover was
correlated linearly with the plasma iron concentrations for both the Hfe KO
and C57BL6 mice (Hfe KO, r2 0.79, P 0.001; C57BL6, r2 0.60, P 0.001).
There was no significant difference in the plasma iron turnover with increas-
ing plasma iron concentrations in the Hfe KO vs. the control mice (slope, P 
0.20; intercept, P  0.40).











decreased transferrin-bound iron uptake and to the incorrect
sensing of body iron stores by the duodenum.
A number of studies have examined TfR1 expression in the
duodenum. TfR1 expression is high in the crypt relative to the
villus region, consistent with the crypt cells undergoing rapid
proliferation and having a high requirement for iron. The level
of expression in the crypt is not altered by the iron status of the
body, allowing the uptake of transferrin-bound iron to vary with
transferrin saturation and reflect body iron levels (10, 43–46).
Impairment of this uptake process as a consequence of muta-
tions in HFE is the proposed defect in HH. Recently, a cohort
of Italian patients with a mutation in the TfR2 gene (termed
HFE3) were reported to develop iron overload (47), suggesting
that TfR2, a recently described second transferrin receptor, plays
a role in the regulation of iron homeostasis. The mechanism by
which loss of function of TfR2 leads to iron storage remains to
be established. West et al. (48) have reported that, unlike TfR1,
TfR2 does not form a stable complex with HFE-2M). Thus, the
mechanism by which it inf luences iron absorption may
not involve the pathway of iron sensing in which HFE-2M
participates.
In conclusion, our study provides direct evidence to support
the hypothesis that HFE regulates the uptake of transferrin-
bound iron from the plasma by the duodenum. Disruption of this
HFE-dependent regulation of transferrin-bound iron uptake by
the crypt cells in HH would decrease the iron uptake by the crypt
cells, so that intracellular iron levels would not correctly reflect
the high plasma iron levels found in HH. As a result, the
differentiating enterocytes would be programmed to absorb iron
inappropriately.
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